Overview

RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa

Status:
Active, not recruiting

Trial end date:
2035-04-24

Target enrollment:
0

Participant gender:
All

Summary

Currently enrolling a total of 12 patients for Phase 2a of the study: 6 patients must have VA of no-better-than hand motion in the study eye, and 6 patients must have VA in the study eye to range from no-worse-than count fingers to 20/200 vision.

Phase:

Phase 1/Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Allergan
RetroSense Therapeutics

Criteria

Inclusion criteria:

Participants must meet all of the following criteria.

1. Age >= 18 years

2. Signed and dated written informed consent obtained from the patient.

3. Ability to comply with testing and all protocol tests.

Exclusion criteria:

Any one of the following will exclude patients from being enrolled into the study:

1. Unable or unwilling to meet requirements of the study;

2. Participation in a clinical study (ocular or non-ocular) with an investigational drug,
agent or therapy in the past six months